Complexes between CD40 and compounds comprising benzimidazole moieties

Patent metadata

Field	Value
Publication number	US-12474348-B2
Application number	US-202217823356-A
Country	US
Kind code	B2
Filing date	Aug 30, 2022
Priority date	Jun 18, 2015
Publication date	Nov 18, 2025
Grant date	Nov 18, 2025

Abstract

It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. Anew assay for identifying compounds with this mechanism of action is also disclosed.

First claim

The invention claimed is:

1 . A complex comprising a trimeric protein that is a TNF superfamily member and a compound comprising a benzimidazole moiety that is capable of binding to the trimeric protein that is a TNF superfamily member, whereby the compound-trimer complex binds to a requisite TNF superfamily receptor and modulates the signalling induced by the trimeric protein that is a TNF superfamily member through the receptor,
wherein the TNF superfamily member is TNFα and the requisite receptor is TNF receptor, or wherein the TNF superfamily member is CD40L and the requisite receptor is CD40.

2 . The complex of claim 1 , wherein the compound antagonises the signalling induced by the trimer through the receptor.

3 . The complex of claim 2 , wherein:
a) the compound increases the stability of the trimeric form of the TNF superfamily member compared to the stability of the trimeric form of the TNF superfamily member in the absence of the compound; or b) the compound increases the stability of the trimeric form of the TNF superfamily member compared to the stability of the trimeric form of the TNF superfamily member in the absence of the compound and the increase in stability results in an increase in the thermal transition midpoint (T m ) of the trimeric form of the TNF superfamily member of at least 1° C., of at least 10° C., or between 10° C. and 20° C.

4 . The complex of claim 1 , wherein:
a) the compound increases the binding affinity of the TNF superfamily member to the requisite receptor compared to the binding affinity of the TNF superfamily member to its receptor in the absence of the compound; b) the compound increases the binding affinity of the TNF superfamily member to the requisite receptor compared to the binding affinity of the TNF superfamily member to its receptor in the absence of the compound and the compound increases the binding affinity of the TNF superfamily member to the requisite receptor by increasing the on rate (k on-r ) and/or decreasing the off rate (k off-r ) compared to the k on-r and k off-r values for binding of the TNF superfamily member to its receptor in the absence of the compound; c) the compound increases the binding affinity of the TNF superfamily member to the requisite receptor compared to the binding affinity of the TNF superfamily member to its receptor in the absence of the compound the compound increases the binding affinity of the TNF superfamily member to the requisite receptor by increasing the on rate (k on-r ) compared to the k on-r value for binding of the TNF superfamily member to its receptor in the absence of the compound; d) the compound decreases the K D-r of the TNF superfamily member to the requisite receptor compared to the K D-r of the TNF superfamily member to its receptor in the absence of the compound, wherein the compound decreases the K D-r of the TNF superfamily member to the requisite receptor by at least 10 times compared to the K D-r of the TNF superfamily member to its receptor in the absence of the compound and the K D-r value of the TNF superfamily member for binding to the requisite receptor in the presence of the compound is less than 10 nM; or e) the compound decreases the K D-r of the TNF superfamily member to the requisite receptor compared to the K D-r of the TNF superfamily member to its receptor in the absence of the compound, wherein the compound decreases the K D-r of the TNF superfamily member to the requisite receptor by at least 4 times compared to the K D-r of the TNF superfamily member to its receptor in the absence of the compound and the K D-r value of the TNF superfamily member for binding to the requisite receptor in the presence of the compound is less than 600 pM or less than 200 pM.

5 . The complex of claim 1 , wherein:
a) said compound has an IC 50 value of 500 nM or less.

6 . A pharmaceutical composition comprising the complex of claim 1 and a pharmaceutically acceptable carrier.

Assignees

• UCB Biopharma SRL

Inventors

• O′Connell James Philip
• Porter John Robert
• Lawson Alastair
• Kroeplien Boris
• Rapecki Stephen Edward
• Norman Timothy John
• Warrellow Graham John

Classifications

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61K47/6425

  the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell · CPC title

• G01N33/6854

  Immunoglobulins · CPC title

• C07D471/04

  Ortho-condensed systems · CPC title